Hans Moebius's most recent trade in Athira Pharma Inc was a trade of 10,000 Common Stock done . Disclosure was reported to the exchange on Jan. 4, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 10,000 | 91,482 | - | 0 | Common Stock | |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2023 | 7,882 | 0 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 02 Jun 2023 | 7,882 | 81,482 | - | 1.4 | 10,641 | Common Stock |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 2.41 per share. | 02 Jun 2023 | 7,764 | 73,600 | - | 2.4 | 18,711 | Common Stock |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 3.29 per share. | 15 Nov 2022 | 5,000 | 65,836 | - | 3.3 | 16,442 | Common Stock |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 13 Oct 2022 | 7,881 | 60,836 | - | 1.3 | 10,639 | Common Stock |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2022 | 7,881 | 7,882 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 2.88 per share. | 28 Jun 2022 | 10,000 | 52,955 | - | 2.9 | 28,800 | Common Stock |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 12.51 per share. | 18 Jan 2022 | 829 | 31,256 | - | 12.5 | 10,371 | Common Stock |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 21 Jul 2021 | 15,762 | 30,427 | - | 1.4 | 21,279 | Common Stock |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2021 | 15,762 | 15,763 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2021 | 12,610 | 0 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.35 per share. | 21 Jul 2021 | 12,610 | 14,665 | - | 1.4 | 17,024 | Common Stock |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 14.45 per share. | 21 Jul 2021 | 2,055 | 2,055 | - | 14.5 | 29,695 | Common Stock |
| Athira Pharma Inc | Hans Moebius | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 72,000 | 72,000 | - | - | Stock Option (Right to Buy) |